Developing, funding and conducting clinical trials in immune tolerance
A clinical trial for individuals with Antiphospholipid Syndrome (APS).
DARE-APS is currently enrolling participants.
If you are 18-70 and have a history of APS, you may be eligible.
Learn more ›
DARE-APS will be conducted at multiple locations across the United States.
A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.